J. Backstrom

发表

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

G. Mufti, P. Greenberg, G. Garcia-Manero, 2022, Leukemia.

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

G. Mufti, L. Saft, A. Porwit, 2014, Haematologica.

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

G. Garcia-Manero, P. Fenaux, C. Finelli, 2021, Blood.

Teratogenic Drugs and Risk Management: An Implementation Assessment

F. Houn, R. Bwire, J. Backstrom, 2014, Therapeutic innovation & regulatory science.

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine *

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, European journal of haematology.

Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, British journal of haematology.

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

J. Hainsworth, T. Cosgriff, A. Cohn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

J. Byrd, G. Mufti, J. Bennett, 2007 .

Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS).

T. Cosgriff, R. Lyons, I. Fernando, 2007 .

Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission

G. Mufti, J. Bennett, P. Fenaux, 2008 .

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

A. Hagemeijer, G. Mufti, B. Skikne, 2009 .

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)

G. Mufti, B. Quesnel, G. Garcia-Manero, 2008 .

Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

p 53 protein expression independently predicts outcome in patients with lowerrisk lowerrisk lowerrisk myelodysplastic syndromes with del ( 5 q )

G. Mufti, L. Saft, A. Porwit, 2022 .

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

L. Silverman, G. Mufti, P. Fenaux, 2008 .

58 Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients

P. Fenaux, E. Hellström-Lindberg, A. List, 2011 .

G. Mufti, G. Garcia-Manero, P. Fenaux, 2020 .

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

L. Silverman, G. Mufti, P. Fenaux, 2008 .

Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q.

P. Fenaux, A. List, J. Backstrom, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

S. Gore, P. Fenaux, E. Hellström-Lindberg, 2008, Ecancermedicalscience.

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.

S. Perrotta, M. Cappellini, V. Viprakasit, 2022, The Lancet. Haematology.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

H. Dombret, G. Mufti, P. Fenaux, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the Believe Trial

S. Perrotta, M. Cappellini, V. Viprakasit, 2020 .

Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.

T. Cosgriff, R. Lyons, J. Backstrom, 2006 .

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

R. Larson, B. Peterson, J. Holland, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study

J. Byrd, G. Mufti, J. Bennett, 2012 .

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, Critical reviews in oncology/hematology.

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

A. Glasmacher, P. Fenaux, A. List, 2012, Leukemia.

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study

A. Mead, S. Verstovsek, T. Gerike, 2020 .

Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial

M. Cappellini, V. Viprakasit, T. Coates, 2020 .

E. Neufeld, M. Cappellini, V. Viprakasit, 2020 .

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

R. Larson, B. Peterson, L. Silverman, 2005 .

G. Mufti, G. Garcia-Manero, P. Fenaux, 2021, Journal of clinical medicine.

REMS pharmacy tasks: The adoption of an innovative electronic support system.

J. Chapman, J. Backstrom, P. Sheehan, 2019, Journal of the American Pharmacists Association.

Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study

J. Hasford, A. Glasmacher, P. Fenaux, 2011 .

EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

H. Dombret, G. Mufti, P. Fenaux, 2008 .

Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study

G. Mufti, P. Greenberg, A. Verma, 2020 .

E. Neufeld, M. Cappellini, V. Viprakasit, 2023, European journal of haematology.

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.

P. Greenberg, G. Garcia-Manero, P. Fenaux, 2022, Blood.